EconPapers    
Economics at your fingertips  
 

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, Maria Karagianni, Petra C. Schwalie, Laura Lauener, Eleni Maria Varypataki, Marine Richard, Esther Bommer, Johannes Sam, Stefanie Joller, Mario Perro, Floriana Cremasco, Leo Kunz, Emilio Yanguez, Tamara Hüsser, Ramona Schlenker, Marisa Mariani, Vinko Tosevski, Sylvia Herter, Marina Bacac, Inja Waldhauer, Sara Colombetti, Xavier Gueripel, Stephan Wullschleger, Melanie Tichet, Douglas Hanahan, Haydn T. Kissick, Stephane Leclair, Anne Freimoser-Grundschober, Stefan Seeber, Volker Teichgräber, Rafi Ahmed, Christian Klein () and Pablo Umaña ()
Additional contact information
Laura Codarri Deak: Roche Innovation Center Zurich
Valeria Nicolini: Roche Innovation Center Zurich
Masao Hashimoto: Emory University School of Medicine
Maria Karagianni: Roche Innovation Center Zurich
Petra C. Schwalie: Roche Innovation Center Basel
Laura Lauener: Roche Innovation Center Zurich
Eleni Maria Varypataki: Roche Innovation Center Zurich
Marine Richard: Roche Innovation Center Zurich
Esther Bommer: Roche Innovation Center Zurich
Johannes Sam: Roche Innovation Center Zurich
Stefanie Joller: Roche Innovation Center Zurich
Mario Perro: Roche Innovation Center Zurich
Floriana Cremasco: Roche Innovation Center Zurich
Leo Kunz: Roche Innovation Center Zurich
Emilio Yanguez: Roche Innovation Center Zurich
Tamara Hüsser: Roche Innovation Center Zurich
Ramona Schlenker: Roche Innovation Center Munich
Marisa Mariani: Roche Innovation Center Zurich
Vinko Tosevski: Roche Innovation Center Zurich
Sylvia Herter: Roche Innovation Center Zurich
Marina Bacac: Roche Innovation Center Zurich
Inja Waldhauer: Roche Innovation Center Zurich
Sara Colombetti: Roche Innovation Center Zurich
Xavier Gueripel: Roche Innovation Center Zurich
Stephan Wullschleger: School of Life Sciences, EPFL
Melanie Tichet: School of Life Sciences, EPFL
Douglas Hanahan: School of Life Sciences, EPFL
Haydn T. Kissick: Emory University School of Medicine
Stephane Leclair: Roche Innovation Center Munich
Anne Freimoser-Grundschober: Roche Innovation Center Zurich
Stefan Seeber: Roche Innovation Center Munich
Volker Teichgräber: Roche Innovation Center Basel
Rafi Ahmed: Emory University School of Medicine
Christian Klein: Roche Innovation Center Zurich
Pablo Umaña: Roche Innovation Center Zurich

Nature, 2022, vol. 610, issue 7930, 161-172

Abstract: Abstract Expansion and differentiation of antigen-experienced PD-1+TCF-1+ stem-like CD8+ T cells into effector cells is critical for the success of immunotherapies based on PD-1 blockade1–4. Hashimoto et al. have shown that, in chronic infections, administration of the cytokine interleukin (IL)-2 triggers an alternative differentiation path of stem-like T cells towards a distinct population of ‘better effector’ CD8+ T cells similar to those generated in an acute infection5. IL-2 binding to the IL-2 receptor α-chain (CD25) was essential in triggering this alternative differentiation path and expanding better effectors with distinct transcriptional and epigenetic profiles. However, constitutive expression of CD25 on regulatory T cells and some endothelial cells also contributes to unwanted systemic effects from IL-2 therapy. Therefore, engineered IL-2 receptor β- and γ-chain (IL-2Rβγ)-biased agonists are currently being developed6–10. Here we show that IL-2Rβγ-biased agonists are unable to preferentially expand better effector T cells in cancer models and describe PD1-IL2v, a new immunocytokine that overcomes the need for CD25 binding by docking in cis to PD-1. Cis binding of PD1-IL2v to PD-1 and IL-2Rβγ on the same cell recovers the ability to differentiate stem-like CD8+ T cells into better effectors in the absence of CD25 binding in both chronic infection and cancer models and provides superior efficacy. By contrast, PD-1- or PD-L1-blocking antibodies alone, or their combination with clinically relevant doses of non-PD-1-targeted IL2v, cannot expand this unique subset of better effector T cells and instead lead to the accumulation of terminally differentiated, exhausted T cells. These findings provide the basis for the development of a new generation of PD-1 cis-targeted IL-2R agonists with enhanced therapeutic potential for the treatment of cancer and chronic infections.

Date: 2022
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/s41586-022-05192-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:610:y:2022:i:7930:d:10.1038_s41586-022-05192-0

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-022-05192-0

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:nature:v:610:y:2022:i:7930:d:10.1038_s41586-022-05192-0